Aslan Financial Statements From 2010 to 2021

ASLN -  USA Stock  

USD 1.51  0.01  0.66%

Aslan Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Aslan Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aslan Pharmaceuticals financial statements helps investors assess Aslan Pharmaceuticals' valuation, profitability, and current liquidity needs.
We have found fifty-nine available fundamental signals for Aslan Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. We recommend to validate Aslan Pharmaceuticals' prevailing fundamental drivers against the all of the trends between 2010 and 2021.
Aslan Pharmaceuticals Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 16 Million. Invested Capital is expected to rise to about 10.4 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (16.6 M).

Aslan Financial Statements 

 
Refresh
Check Aslan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aslan main balance sheet or income statement drivers, such as Cost of Revenue of 400.6 K, Gross Profit of 2.4 M or Interest Expense of 1.1 M, as well as many exotic indicators such as Asset Turnover of 0.0707, Current Ratio of 1.49 or Gross Margin of 0.8. Aslan financial statements analysis is a perfect complement when working with Aslan Pharmaceuticals Valuation or Volatility modules. It can also supplement various Aslan Pharmaceuticals Technical models. Please continue to the analysis of Aslan Pharmaceuticals Correlation against competitors.

Aslan Pharmaceuticals Revenues

2.77 MillionShare

Aslan Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets25.1 M16.1 M45.4 M
Decreasing
Slightly volatile
Cash and Equivalents21.7 M14.3 M41.7 M
Decreasing
Slightly volatile
Investments154.8 K137.9 K226.5 K
Decreasing
Slightly volatile
Investments Current123.4 K124.1 K135.6 K
Decreasing
Slightly volatile
Investments Non Current189.2 K180.4 K232.9 K
Decreasing
Slightly volatile
Property Plant and Equipment Net523.6 K475.9 K432.4 K
Increasing
Slightly volatile
Trade and Non Trade Receivables634.3 K476 K979.6 K
Decreasing
Slightly volatile
Trade and Non Trade Payables6.9 M6.6 M4.9 M
Increasing
Slightly volatile
Goodwill and Intangible Assets164160M
Increasing
Stable
Total Liabilities25.4 M26.2 M16.6 M
Increasing
Slightly volatile
Shareholders Equity(10.7 M)(10.5 M)27.9 M
Decreasing
Slightly volatile
Current Assets22.5 M15.5 M42.7 M
Decreasing
Slightly volatile
Assets Non Current594.7 K579.4 K2.6 M
Increasing
Stable
Current Liabilities9.5 M10.7 M5.5 M
Increasing
Slightly volatile
Liabilities Non Current15.9 M15.6 M11 M
Increasing
Slightly volatile
Total Debt18.2 M19.3 M11.5 M
Increasing
Slightly volatile
Debt Current3.2 M3.8 M800.4 K
Increasing
Slightly volatile
Debt Non Current15.8 M15.5 M11 M
Increasing
Slightly volatile
Shareholders Equity USD(10.7 M)(10.5 M)27.9 M
Decreasing
Slightly volatile
Cash and Equivalents USD21.7 M14.3 M41.7 M
Decreasing
Slightly volatile
Total Debt USD18.2 M19.3 M11.5 M
Increasing
Slightly volatile

Aslan Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues2.8 M2.7 M7.9 M
Decreasing
Slightly volatile
Cost of Revenue400.6 K468.3 K247.1 K
Increasing
Slightly volatile
Selling General and Administrative Expense8.6 M7.2 M7.7 M
Increasing
Slightly volatile
Research and Development Expense13.4 M9.3 M16.1 M
Increasing
Stable
Operating Expenses16.9 M16.5 M25.3 M
Increasing
Slightly volatile
Interest Expense1.1 M1.2 M649.8 K
Increasing
Slightly volatile
Income Tax Expense506.2 K469.2 K126.1 K
Increasing
Slightly volatile
Weighted Average Shares198.4 M192.2 M170.3 M
Increasing
Slightly volatile
Weighted Average Shares Diluted198.5 M192.2 M158.4 M
Increasing
Slightly volatile
Revenues USD2.8 M2.7 M7.9 M
Decreasing
Slightly volatile
Gross Profit2.4 M2.3 M7.7 M
Decreasing
Slightly volatile

Aslan Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(4.1 K)(3.8 K)(2.2 M)
Decreasing
Stable
Net Cash Flow from Financing7.4 M7.2 M27.1 M
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (246.9 K)(240.5 K)347.5 K
Increasing
Slightly volatile
Issuance Purchase of Equity Shares7.8 M7.6 M21.8 M
Decreasing
Stable
Net Cash Flow from InvestingK927(2.3 M)
Decreasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents(8.1 M)(7.9 M)10.6 M
Decreasing
Slightly volatile
Share Based Compensation537.9 K345.8 K1.1 M
Decreasing
Slightly volatile
Depreciation Amortization and Accretion298.7 K295.1 K161 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity2.031.885(0.7408)
Increasing
Slightly volatile
Gross Margin0.80.780.9246
Decreasing
Slightly volatile
Asset Turnover0.07070.07110.0776
Decreasing
Slightly volatile
Sales per Share0.08230.08280.0904
Decreasing
Slightly volatile
Price to Sales Ratio19.6619.7821.6011
Decreasing
Slightly volatile
Price to Book Value(7.17)(6.651)(1.4279)
Decreasing
Slightly volatile
Debt to Equity Ratio(2.71)(2.51)(1.357)
Decreasing
Slightly volatile
Current Ratio1.491.4559.7462
Decreasing
Slightly volatile
Book Value per Share(0.28)(0.272)0.7408
Decreasing
Slightly volatile
Tangible Assets Book Value per Share0.610.4181.2478
Decreasing
Slightly volatile

Aslan Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization72.4 M69.5 M107.8 M
Decreasing
Slightly volatile
Enterprise Value72.9 M76.1 M82.5 M
Decreasing
Slightly volatile
Invested Capital10.4 M10.4 M7.6 M
Increasing
Slightly volatile
Average Equity(9.2 M)(9 M)28.1 M
Decreasing
Slightly volatile
Average Assets16 M15.6 M45.2 M
Decreasing
Slightly volatile
Invested Capital Average12.3 M13.7 M7.1 M
Increasing
Slightly volatile
Tangible Asset Value23.1 M16.1 M43.3 M
Decreasing
Slightly volatile
Working CapitalM4.8 M36.5 M
Decreasing
Slightly volatile

Aslan Fundamental Market Drivers

Forward Price Earnings-3.80
Shares Short Prior Month1.72M
Average Daily Volume Last 10 Day716.75k
Average Daily Volume In Three Month1.06M
Date Short Interest15th of June 2021
Fifty Day Average2.2241
Two Hundred Day Average2.7960

Aslan Upcoming Events

Upcoming Quarterly Report8th of November 2021
Next Earnings Report28th of April 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End28th of April 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Aslan Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Aslan Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Aslan Pharmaceuticals investors use historical funamental indicators, such as Aslan Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Aslan Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Aslan Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aslan Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aslan Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aslan Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Cost of Revenue468.3 K400.6 K
Revenues2.7 M2.8 M
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people.

Aslan Pharmaceuticals Investors Sentiment

The influence of Aslan Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Aslan. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - ASLN

Aslan Pharmaceuticals Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Aslan Pharmaceuticals. What is your sentiment towards investing in Aslan Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Aslan Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals and Biocardia. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Aslan Pharmaceuticals Correlation against competitors. Note that the Aslan Pharmaceuticals information on this page should be used as a complementary analysis to other Aslan Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Aslan Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.